The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Circulating androgen receptor and serum chromogranin A in castration-resistant prostate cancers (CRPC) patients treated with abiraterone and enzalutamide.
 
Vincenza Conteduca
No Relationships to Disclose
 
Samanta Salvi
No Relationships to Disclose
 
Valentina Casadio
No Relationships to Disclose
 
Cristian Lolli
No Relationships to Disclose
 
Giorgia Gurioli
No Relationships to Disclose
 
Giuseppe Schepisi
No Relationships to Disclose
 
Filippo Martignano
No Relationships to Disclose
 
Cecilia Menna
No Relationships to Disclose
 
Salvatore Luca Burgio
No Relationships to Disclose
 
Sara Testoni
No Relationships to Disclose
 
Gerhardt Attard
Honoraria - Astellas Pharma; Janssen
Consulting or Advisory Role - Abbott Laboratories; Astellas Pharma; Bayer; ESSA; Janssen-Cilag; Medivation; Millennium; Novartis; Ventana Medical Systems; Veridex
Speakers' Bureau - Astellas Pharma; Janssen; Sanofi; Takeda; Ventana Medical Systems
Research Funding - Arno Therapeutics (Inst); AstraZeneca (Inst); Janssen (Inst)
Patents, Royalties, Other Intellectual Property - I am on The ICR rewards to inventors list of abiraterone acetate.
Travel, Accommodations, Expenses - Abbott Laboratories; Astellas Pharma; Astellas Pharma (I); Bayer; ESSA; Janssen; Janssen (I); Medivation; Ventana Medical Systems
Other Relationship - Institute of Cancer Research
 
Ugo De Giorgi
Consulting or Advisory Role - Astellas Pharma; Janssen-Cilag; Sanofi